Elsevier

Pregnancy Hypertension

Volume 11, January 2018, Pages 99-104
Pregnancy Hypertension

The role of angiogenic biomarkers and uterine artery Doppler in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome

https://doi.org/10.1016/j.preghy.2018.01.008Get rights and content

Highlights

  • We found a 9% of PE or IUGR and 11% of flares in pregnant women with SLE or APS.

  • mUtA-PI and sFlt-1/PlGF showed no differences between normal and SLE flare groups.

  • In the second half of pregnancy, PE or IUGR showed higher mUtA-PI and sFlt-1/PlGF.

  • mPI-UtA and sFlt1/PlGF may help to differentiate PE or IUGR from SLE flare.

Abstract

Objective

To evaluate the usefulness of the uterine artery mean pulsatility index (mPI-UtA) and the sFlt-1/PlGF ratio in women with systemic lupus erythematosus (SLE) or antiphospholipid syndrome (APS) for the prediction of placental dysfunction-related adverse outcomes (AO), namely pre-eclampsia (PE) and intrauterine growth restriction (IUGR), and for differential diagnosis between PE and SLE flares.

Study design

Observational prospective cohort study of 57 pregnant women with SLE or APS.

Main outcome measures

mPI-UtA and sFlt-1/PlGF ratio in maternal serum were obtained at four gestational age periods (11–14, 19–22, 24–29 and 32–34 weeks). Comparisons among pregnancies with normal outcome, SLE flare and AO were performed.

Results

Overall, we had 44 ongoing pregnancies (36 with SLE and 8 with APS) of which most (n = 35, 80%) were uncomplicated. The overall rate of AO was 9% (n = 4), that was diagnosed at a mean (SD) gestational age of 34.1 (7.5) weeks. Five SLE patients (14%) suffered a SLE flare. No differences for these markers were found between normal pregnancies and those affected by SLE flare. mUtA-PI values were significantly higher in the AO group when compared with normal and SLE flare groups, at 19–22 weeks (1.52, 0.95 and 0.76) and 32–34 weeks (1.13, 0.68 and 0.65), respectively. The sFlt-1/PlGF ratio was significantly higher in the AO group at 24–29 weeks (191.1, 3.1 and 9.2), respectively.

Conclusion

Our preliminary results indicate that mPI-UtA and sFlt1/PlGF ratio may be useful to predict AO in women with SLE, and to make the differential diagnosis with a lupus flare.

Introduction

Systemic lupus erythematosus (SLE) disproportionately affects women during their childbearing ages. Pregnancy in patients with SLE, particularly in those with antiphospholipid syndrome (APS), but also with antiphospholipid antibodies (aPL) alone, is associated with an increased risk of adverse outcomes (AO) due to placental insufficiency and these patients have a much higher risk of preeclampsia (PE) (14–23%) [1], [2], [3], [4], preterm delivery (20–31%) [1], [3], [5], intrauterine growth restriction (IUGR) (5–23%) and intrauterine fetal death [6], [7].

PE is a specific pregnancy syndrome that usually manifests with high systemic blood pressure (SBP) and proteinuria, and resolves following delivery. Severe PE is characterized by very high SBP, as well as other multiorganic manifestations, including cerebral and visual symptoms, thrombocytopenia, hemolysis, renal insufficiency, and liver involvement [8]. In SLE patients, differentiating between disease activity, particularly lupus nephritis (LN), and PE can be challenging because they share symptoms such as hypertension or proteinuria.

Several angiogenic factors have been identified as biomarkers of placental dysfunction. Changes in the ratio between the pro-angiogenic placental growth factor (PlGF) and the anti-angiogenic factor soluble fms-like tyrosine kinase-1 (sFlt-1) has demonstrated to be useful for the prediction and diagnosis of PE, especially the early-onset forms [9], [10]. Moreover, detection of increased mean pulsatility index in the uterine arteries (mPI-UtA) has also a high sensitivity and specificity for predicting PE and IUGR [11]. Some combined algorithms using both predictive tools have been proposed for detecting patients at high risk of developing placental dysfunction-related diseases [12]. Moreover, previous results have pointed out that the sFlt-1/PlGF ratio as well as the mPI-UtA can be useful to differentiate between PE and SLE or APS nephropathies [12], [13].

The aim of our study was to assess the value of the mPI-UtA and sFlt-1/PlGF ratio as early markers of placental dysfunction in pregnant patients with either SLE or APS, and to describe how these angiogenesis markers behave in SLE patients with disease activity.

Section snippets

Study population

Pregnant patients with either SLE diagnosis, with or without aPL, or with APS referred to our high-risk pregnancy clinic from the first trimester of pregnancy were consecutively included from January 2011 to December 2015. SLE and APS diagnosis were established according to the American College of Rheumatology [14] and Sydney criteria [15], respectively. We excluded patients with poorly controlled arterial hypertension, those who were lost for follow-up during pregnancy or delivery, and when

Results

Fifty-seven patients were consecutively included, 46 (81%) with SLE and 11 (19%) with APS diagnosis. Fig. 1 shows the flow chart of the study population from enrollment to final outcome. Among SLE patients, 10 (22%) had spontaneous miscarriage and there were 36 ongoing pregnancies of whom 29 had normal pregnancy outcome (81%), 5 suffered a SLE flare (14%), and 2 (6%) had an AO (1 with early-onset IUGR and abruption placentae at 32 weeks of gestation resulting in severe hypoxic-ischemic

Discussion

Pregnancy in patients with either SLE and/or APS patients is a high risk clinical condition, and these patients are currently recommended not become pregnant until at least 6 months have passed without SLE activity or 12 months since the last episode of LN [26], [27]. In any case, once these patients become pregnant they are more prone to suffering flares or gestational complications such as PE, and it can be extremely difficult to differentiate SLE activity from some AO like PE, using only

Funding

This work was supported by the Instituto de Salud Carlos III (Spanish Ministry of Economy, Industry and Competitiveness) and cofunded by the European Regional Development Fund [project PI10/02102].

Conflicts of interest

Ignacio Herraiz and Alberto Galindo have received lecture fees and consultancy payments from Roche Diagnostics. The other authors do not report any conflicts of interest. The authors alone are responsible for the content and writing of this article.

References (34)

  • P.E. Georgiou et al.

    Outcome of lupus pregnancy: a controlled study

    Rheumatol. Oxf. Engl.

    (2000)
  • E.F. Chakravarty et al.

    Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis

    Arthritis. Rheum.

    (2006)
  • P. Ambrósio et al.

    Lupus and pregnancy–15 years of experience in a tertiary center

    Clin. Rev. Allergy Immunol.

    (2010)
  • P.I. Gómez-Arriaga et al.

    Uterine artery Doppler and sFlt-1/PlGF ratio: prognostic value in early-onset pre-eclampsia

    Ultrasound. Obstet. Gynecol.

    (2014)
  • G. Pagani et al.

    The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus: uterine artery pulsatility in pregnant SLE patients

    Prenat. Diagn.

    (2015)
  • I. Herraiz et al.

    Angiogenesis-related biomarkers (sFlt-1/PLGF) in the prediction and diagnosis of placental dysfunction: an approach for clinical integration

    Int. J. Mol. Sci.

    (2015)
  • G. de Jesus et al.

    The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis

    Lupus

    (2014)
  • Cited by (15)

    • Pregnancy-related complications in systemic lupus erythematosus

      2022, Journal of Autoimmunity
      Citation Excerpt :

      Several angiogenic factors have been considered biomarkers of placental dysfunction. Recent findings have shown that a higher ratio of anti-angiogenic sFlt-1/proangiogenic PlGF is involved in the severity of APOs in patients with SLE [11,55]. sFlt-1, also known as soluble VEGF receptor-1 (sVEGFR-1) is a potential inhibitor of PlGF and VEGF [56].

    • Systemic lupus erythematosus and pregnancy: Strategies before, during and after pregnancy to improve outcomes

      2021, Revista Colombiana de Reumatologia
      Citation Excerpt :

      Doppler ultrasound findings can also be helpful in making a differential diagnosis between PE and SLE flares. In a prospective cohort study, mean pulsatility index of uterine arteries at 32–34 weeks was higher in patients with PE and/or IUGR compared to LN flares.65 In general, the diagnosis of preeclampsia is clinical.

    • Eculizumab in Early-Stage Pregnancy

      2020, Kidney International Reports
      Citation Excerpt :

      In clinical practice, the presence of common characteristics among these entities makes reaching a precise diagnosis difficult. In PE/HELLP syndrome, the elevation of the sFlt-1/PlGF ratio5 and their clinical resolution after delivery can be of help in differential diagnosis.6 aHUS usually develops postpartum, whereas PE/HELLP syndrome usually occur during the second half of pregnancy.S7 Regardless of the definitive diagnosis, whenever TMA is found along with compromised fetal viability the use of eculizumab could potentially prolong the pregnancy.

    • Role of sFlt-1/PIGF ratio and uterine Doppler in pregnancies with chronic kidney disease suspected with Pre-eclampsia or HELLP syndrome

      2020, Pregnancy Hypertension
      Citation Excerpt :

      Rolfo et al. already demonstrated that sFlt-1/PIGF is a useful tool for the diagnosis of PE in women with CKD [27]. Rodríguez-Almaraz et al. reported an association of sFlt-1/PIGF as well as mUtA-PI and development of PE or FGR in women with SLE [28]. However, the number of included women with CKD were small.

    • Angiogenic markers could predict adverse pregnancy outcomes

      2022, Clinical and Experimental Medicine
    View all citing articles on Scopus
    View full text